Is irritable bowel syndrome an organic disorder?

World Journal of Gastroenterology

Volumn 20, Issue 2, 2014, Pages 384-400

  El Salhy, Magdy ^a,b   Gundersen, Doris ^c   Gilja, Odd Helge ^b   Hatlebakk, Jan Gunnar ^b   Hausken, Trygve ^b  

^a Stord Helse Fonna Hospital   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Helse Fonna ^*  (Norway)

Author keywords

Cholecystokinin; Dysmotility; Endocrine cells; Enteric nervous system; Ghrelin; Peptide YY; Secretin; Secretion; Serotonin; Visceral hypersensitivity

Indexed keywords

CHOLECYSTOKININ; GASTRIN; GHRELIN; PEPTIDE YY; SECRETIN; SEROTONIN; SOMATOSTATIN;

CD4+ T LYMPHOCYTE; ENDOCRINE CELL; EPITHELIUM CELL; FUNCTIONAL DISEASE; HUMAN; HYPERSENSITIVITY; IMMUNOCOMPETENT CELL; INTESTINAL DYSMOTILITY; INTESTINE INNERVATION; IRRITABLE COLON; LAMINA PROPRIA; MENTAL STRESS; MICROVILLUS; NEUROENDOCRINE SYSTEM; REVIEW; ABDOMINAL PAIN; ANIMAL; COLON; ENTEROENDOCRINE CELL; GASTROINTESTINAL MOTILITY; INNERVATION; IRRITABLE BOWEL SYNDROME; METABOLISM; NEUROSECRETORY CELL; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION;

ABDOMINAL PAIN; ANIMALS; COLON; ENTEROENDOCRINE CELLS; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; NEUROENDOCRINE CELLS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84892895251     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i2.384     Document Type: Review

References (321)

1. Quigley EM, Locke GR, Mueller-Lissner S, Paulo LG, Tytgat GN, Helfrich I, Schaefer E. Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther 2006; 24: 411-419 [PMID: 16842469 DOI: 10.1111/j.1365-2036.2006.02989.x]
2. Vandvik PO, Lydersen S, Farup PG. Prevalence, comorbidity and impact of irritable bowel syndrome in Norway. Scand J Gastroenterol 2006; 41: 650-656 [PMID: 16716962 DOI: 10.1080/00365520500442542]
3. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-1580 [PMID: 8359066]
4. Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 1910-1915 [PMID: 12190153 DOI: 10.1111/j.1572-0241.2002.05913.x]
5. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first populationbased survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002; 47: 225-235 [PMID: 11837727]
6. Zhao Y, Zou D, Wang R, Ma X, Yan X, Man X, Gao L, Fang J, Yan H, Kang X, Yin P, Hao Y, Li Q, Dent J, Sung J, Halling K, Wernersson B, Johansson S, He J. Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impact. Aliment Pharmacol Ther 2010; 32: 562-572 [PMID: 20497141 DOI: 10.1111/ j.1365-2036.2010.04376.x]
7. Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2000; 95: 3176-3183 [PMID: 11095338 DOI: 10.1111/j.1572-0241.2000.03197.x]
8. Barbezat G, Poulton R, Milne B, Howell S, Fawcett JP, Talley N. Prevalence and correlates of irritable bowel symptoms in a New Zealand birth cohort. N Z Med J 2002; 115: U220 [PMID: 12552296]
9. Mearin F, Badía X, Balboa A, Baró E, Caldwell E, Cucala M, Díaz-Rubio M, Fueyo A, Ponce J, Roset M, Talley NJ. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol 2001; 36: 1155-1161 [PMID: 11686214]
10. Boekema PJ, van Dam van Isselt EF, Bots ML, Smout AJ. Functional bowel symptoms in a general Dutch population and associations with common stimulants. Neth J Med 2001; 59: 23-30 [PMID: 11438196]
11. Agréus L, Svärdsudd K, Nyrén O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671-680 [PMID: 7657095]
12. Hillilä MT, Färkkilä MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther 2004; 20: 339-345 [PMID: 15274671 DOI: 10.1111/ j.1365-2036.2004.02034.x]
13. Kay L, Jørgensen T, Jensen KH. The epidemiology of irritable bowel syndrome in a random population: prevalence, incidence, natural history and risk factors. J Intern Med 1994; 236: 23-30 [PMID: 8021568]
14. Hoseini-Asl MK, Amra B. Prevalence of irritable bowel syndrome in Shahrekord, Iran. Indian J Gastroenterol 2003; 22: 215-216 [PMID: 15030032]
15. Karaman N, Türkay C, Yönem O. Irritable bowel syndrome prevalence in city center of Sivas. Turk J Gastroenterol 2003; 14: 128-131 [PMID: 14614640]
16. Celebi S, Acik Y, Deveci SE, Bahcecioglu IH, Ayar A, Demir A, Durukan P. Epidemiological features of irritable bowel syndrome in a Turkish urban society. J Gastroenterol Hepatol 2004; 19: 738-743 [PMID: 15209618 DOI: 10.1111/ j.1440-1746.2004.03367.x]
17. Masud MA, Hasan M, Khan AK. Irritable bowel syndrome in a rural community in Bangladesh: prevalence, symptoms pattern, and health care seeking behavior. Am J Gastroenterol 2001; 96: 1547-1552 [PMID: 11374697 DOI: 10.1111/ j.1572-0241.2001.03760.x]
18. Huerta I, Valdovinos MA, Schmulson M. Irritable bowel syndrome in Mexico. Dig Dis 2001; 19: 251-257 [PMID: 11752845]
19. Kwan AC, Hu WH, Chan YK, Yeung YW, Lai TS, Yuen H. Prevalence of irritable bowel syndrome in Hong Kong. J Gastroenterol Hepatol 2002; 17: 1180-1186 [PMID: 12453277]
20. Lau EM, Chan FK, Ziea ET, Chan CS, Wu JC, Sung JJ. Epidemiology of irritable bowel syndrome in Chinese. Dig Dis Sci 2002; 47: 2621-2624 [PMID: 12452405]
21. Schlemper RJ, van der Werf SD, Vandenbroucke JP, Biemond I, Lamers CB. Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in The Netherlands and Japan. Scand J Gastroenterol Suppl 1993; 200: 33-41 [PMID: 8016569]
22. Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol 1998; 93: 1816-1822 [PMID: 9772037 DOI: 10.1111/ j.1572-0241.1998.00526.x]
23. Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmacol Ther 2004; 19: 1217-1224 [PMID: 15153175 DOI: 10.1111/j.1365-2036.2004.01939.x]
24. Gwee KA, Wee S, Wong ML, Png DJ. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an asian urban community. Am J Gastroenterol 2004; 99: 924-931 [PMID: 15128362 DOI: 10.1111/ j.1572-0241.2004.04161.x]
25. Rajendra S, Alahuddin S. Prevalence of irritable bowel syndrome in a multi-ethnic Asian population. Aliment Pharmacol Ther 2004; 19: 704-706 [PMID: 15023175 DOI: 10.1111/ j.1365-2036.2004.01891.x]
26. Jafri W, Yakoob J, Jafri N, Islam M, Ali QM. Irritable bowel syndrome and health seeking behaviour in different communities of Pakistan. J Pak Med Assoc 2007; 57: 285-287 [PMID: 17629228]
27. Jafri W, Yakoob J, Jafri N, Islam M, Ali QM. Frequency of irritable bowel syndrome in college students. J Ayub Med Coll Abbottabad 2005; 17: 9-11 [PMID: 16599025]
28. Boivin M. Socioeconomic impact of irritable bowel syndrome in Canada. Can J Gastroenterol 2001; 15 Suppl B: 8B-11B [PMID: 11694908]
29. Locke GR, Yawn BP, Wollan PC, Melton LJ, Lydick E, Talley NJ. Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population. Aliment Pharmacol Ther 2004; 19: 1025-1031 [PMID: 15113370 DOI: 10.1111/ j.1365-2036.2004.01938.x]
30. Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology 1980; 79: 283-288 [PMID: 7399231]
31. Kennedy TM, Jones RH, Hungin AP, O'flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut 1998; 43: 770-774 [PMID: 9824603]
32. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-1741 [PMID: 7498636]
33. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17: 643-650 [PMID: 12641512]
34. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992; 304: 87-90 [PMID: 1737146]
35. Bordie AK. Functional disorders of the colon. J Indian Med Assoc 1972; 58: 451-456 [PMID: 4649450]
36. O'Keefe EA, Talley NJ, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci 1995; 50: M184-M189 [PMID: 7614239]
37. Everhart JE, Renault PF. Irritable bowel syndrome in officebased practice in the United States. Gastroenterology 1991; 100: 998-1005 [PMID: 2001837]
38. Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 2004; 54: 495-502 [PMID: 15239910]
39. Harvey RF, Salih SY, Read AE. Organic and functional dis-orders in 2000 gastroenterology outpatients. Lancet 1983; 1: 632-634 [PMID: 6131308]
40. Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep 2009; 11: 265-269 [PMID: 19615301]
41. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987; 1: 963-965 [PMID: 2882351]
42. Sloth H, Jørgensen LS. Chronic non-organic upper abdominal pain: diagnostic safety and prognosis of gastrointestinal and non-intestinal symptoms. A 5-to 7-year followup study. Scand J Gastroenterol 1988; 23: 1275-1280 [PMID: 2471256]
43. Gralnek IM, Hays RD, Kilbourne AM, Chang L, Mayer EA. Racial differences in the impact of irritable bowel syndrome on health-related quality of life. J Clin Gastroenterol 2004; 38: 782-789 [PMID: 15365405]
44. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-660 [PMID: 10982758]
45. Whitehead WE, Burnett CK, Cook EW, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 2248-2253 [PMID: 8943980]
46. Pace F, Molteni P, Bollani S, Sarzi-Puttini P, Stockbrügger R, Bianchi Porro G, Drossman DA. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol 2003; 38: 1031-1038 [PMID: 14621276]
47. Drossman DA, Morris CB, Schneck S, Hu YJ, Norton NJ, Norton WF, Weinland SR, Dalton C, Leserman J, Bangdiwala SI. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009; 43: 541-550 [PMID: 19384249 DOI: 10.1097/ MCG.0b013e318189a7f9]
48. Coffin B, Dapoigny M, Cloarec D, Comet D, Dyard F. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2004; 28: 11-15 [PMID: 15041804]
49. Li FX, Patten SB, Hilsden RJ, Sutherland LR. Irritable bowel syndrome and health-related quality of life: a populationbased study in Calgary, Alberta. Can J Gastroenterol 2003; 17: 259-263 [PMID: 12704470]
50. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-1511 [PMID: 11984534]
51. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-87. e1-3 [PMID: 22885331 DOI: 10.1053/j.gastro.2012.08.002]
52. Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003; 163: 265-274 [PMID: 12578506]
53. Gaburri M, Bassotti G, Bacci G, Cinti A, Bosso R, Ceccarelli P, Paolocci N, Pelli MA, Morelli A. Functional gut disorders and health care seeking behavior in an Italian non-patient population. Recenti Prog Med 1989; 80: 241-244 [PMID: 2762661]
54. Barbara G, Stanghellini V. Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut 2009; 58: 1571-1575 [PMID: 19923339 DOI: 10.1136/ gut.2008.169672]
55. Spiller RC. Potential biomarkers. Gastroenterol Clin North Am 2011; 40: 121-139 [PMID: 21333904 DOI: 10.1016/ j.gtc.2011.01.001]
56. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491 [PMID: 16678561 DOI: 10.1053/ j.gastro.2005.11.061]
57. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-1798 [PMID: 17488783 DOI: 10.1136/gut.2007.119446]
58. Quigley EM. The 'con' case. The Rome process and functional gastrointestinal disorders: the barbarians are at the gate! Neurogastroenterol Motil 2007; 19: 793-797 [PMID: 17883430 DOI: 10.1111/j.1365-2982.2007.01000.x]
59. Camilleri M. Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes? The Con Argument. Clin Gastroenterol Hepatol 2009; 8: 129 [PMID: 20182528 DOI: 10.1016/ j.cgh.2009.10.009]
60. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012; 18: 5151-5163 [PMID: 23066308 DOI: 10.3748/wjg.v18.i37.5151]
61. Gladman LM, Gorard DA. General practitioner and hospital specialist attitudes to functional gastrointestinal disorders. Aliment Pharmacol Ther 2003; 17: 651-654 [PMID: 12641513]
62. Lea R, Hopkins V, Hastleton J, Houghton LA, Whorwell PJ. Diagnostic criteria for irritable bowel syndrome: utility and applicability in clinical practice. Digestion 2004; 70: 210-213 [PMID: 15627768 DOI: 10.1159/000082891]
63. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000; 46: 78-82 [PMID: 10601059]
64. Corsetti M, Tack J. Are symptom-based diagnostic criteria for irritable bowel syndrome useful in clinical practice? Digestion 2004; 70: 207-209 [PMID: 15627767 DOI: 10.1159/000082890]
65. Karantanos T, Markoutsaki T, Gazouli M, Anagnou NP, Karamanolis DG. Current insights in to the pathophysiology of Irritable Bowel Syndrome. Gut Pathog 2010; 2: 3 [PMID: 20465787 DOI: 10.1186/1757-4749-2-3]
66. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Irritable bowel syndrome: diagnosis, pathogenesis and treatment options. New York: Nova Science Publishers, Inc., 2012
67. Longstreth GF, Hawkey CJ, Mayer EA, Jones RH, Naesdal J, Wilson IK, Peacock RA, Wiklund IK. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol Ther 2001; 15: 959-964 [PMID: 11421870]
68. Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190-192 [PMID: 6826101]
69. Ansari R, Attari F, Razjouyan H, Etemadi A, Amjadi H, Merat S, Malekzadeh R. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol 2008; 20: 46-50 [PMID: 18090990 DOI: 10.1097/ MEG.0b013e3282f16a62]
70. Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97: 389-396 [PMID: 11866278 DOI: 10.1111/ j.1572-0241.2002.05475.x]
71. Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004; 49: 469-474 [PMID: 15139501]
72. Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010; 105: 1788, 1789-194; quiz 1795 [PMID: 20389294 DOI: 10.1038/ajg.2010.156]
73. May CL, Kaestner KH. Gut endocrine cell development. Mol Cell Endocrinol 2010; 323: 70-75 [PMID: 20025933 DOI: 10.1016/j.mce.2009.12.009]
74. Gunawardene AR, Corfe BM, Staton CA. Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol 2011; 92: 219-231 [PMID: 21518048 DOI: 10.1111/j.1365-2613.2011.00767.x]
75. El-Salhy M, Ostgaard H, Gundersen D, Hatlebakk JG, Hausken T. The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). Int J Mol Med 2012; 29: 723-731 [PMID: 22366773 DOI: 10.3892/ijmm.2012.926]
76. El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG, Hausken T. Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front Biosci (Elite Ed) 2012; 4: 2783-2800 [PMID: 22652678]
77. Tanaka-Shintani M, Watanabe M. Immunohistochemical study of enterochromaffin-like cell in human gastric mucosa. Pathol Int 2007; 57: 572-583 [PMID: 17685928 DOI: 10.1111/ j.1440-1827.2007.02141.x]
78. Lönroth H, Håkanson R, Lundell L, Sundler F. Histamine containing endocrine cells in the human stomach. Gut 1990; 31: 383-388 [PMID: 2186979]
79. Buffa R, Capella C, Fontana P, Usellini L, Solcia E. Types of endocrine cells in the human colon and rectum. Cell Tissue Res 1978; 192: 227-240 [PMID: 699014]
80. Schonhoff SE, Giel-Moloney M, Leiter AB. Minireview: Development and differentiation of gut endocrine cells. Endocrinology 2004; 145: 2639-2644 [PMID: 15044355 DOI: 10.1210/en.2004-0051]
81. Sjölund K, Sandén G, Håkanson R, Sundler F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 1983; 85: 1120-1130 [PMID: 6194039]
82. Sandström O, El-Salhy M. Ageing and endocrine cells of human duodenum. Mech Ageing Dev 1999; 108: 39-48 [PMID: 10366038]
83. El-Salhy M. Ghrelin in gastrointestinal diseases and disorders: a possible role in the pathophysiology and clinical implications (review). Int J Mol Med 2009; 24: 727-732 [PMID: 19885611]
84. Tolhurst G, Reimann F, Gribble FM. Intestinal sensing of nutrients. Handb Exp Pharmacol 2012; (209): 309-335 [PMID: 22249821 DOI: 10.1007/978-3-642-24716-3_14]
85. Lee J, Cummings BP, Martin E, Sharp JW, Graham JL, Stanhope KL, Havel PJ, Raybould HE. Glucose sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 2012; 302: R657-R666 [PMID: 22160540 DOI: 10.1152/ajpregu.00345.2011]
86. Parker HE, Reimann F, Gribble FM. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med 2010; 12: e1 [PMID: 20047700 DOI: 10.1017/ s146239940900132x]
87. Raybould HE. Nutrient sensing in the gastrointestinal tract: possible role for nutrient transporters. J Physiol Biochem 2008; 64: 349-356 [PMID: 19391461]
88. San Gabriel A, Nakamura E, Uneyama H, Torii K. Taste, visceral information and exocrine reflexes with glutamate through umami receptors. J Med Invest 2009; 56 Suppl: 209-217 [PMID: 20224183]
89. Rudholm T, Wallin B, Theodorsson E, Näslund E, Hellström PM. Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. Regul Pept 2009; 152: 8-12 [PMID: 18992283 DOI: 10.1016/ j.regpep.2008.10.002]
90. Sternini C, Anselmi L, Rozengurt E. Enteroendocrine cells: a site of 'taste' in gastrointestinal chemosensing. Curr Opin Endocrinol Diabetes Obes 2008; 15: 73-78 [PMID: 18185066 DOI: 10.1097/MED.0b013e3282f43a73]
91. Sternini C. Taste receptors in the gastrointestinal tract. IV. Functional implications of bitter taste receptors in gastrointestinal chemosensing. Am J Physiol Gastrointest Liver Physiol 2007; 292: G457-G461 [PMID: 17095755 DOI: 10.1152/ajpgi. 00411.2006]
92. Buchan AM. Nutrient Tasting and Signaling Mechanisms in the Gut III. Endocrine cell recognition of luminal nutrients. Am J Physiol 1999; 277: G1103-G1107 [PMID: 10600808]
93. Montero-Hadjadje M, Elias S, Chevalier L, Benard M, Tanguy Y, Turquier V, Galas L, Yon L, Malagon MM, Driouich A, Gasman S, Anouar Y. Chromogranin A promotes peptide hormone sorting to mobile granules in constitutively and regulated secreting cells: role of conserved N-and C-terminal peptides. J Biol Chem 2009; 284: 12420-12431 [PMID: 19179339 DOI: 10.1074/jbc.M805607200]
94. Shooshtarizadeh P, Zhang D, Chich JF, Gasnier C, Schneider F, Haïkel Y, Aunis D, Metz-Boutigue MH. The antimicrobial peptides derived from chromogranin/secretogranin family, new actors of innate immunity. Regul Pept 2010; 165: 102-110 [PMID: 19932135 DOI: 10.1016/j.regpep.2009.11.014]
95. Sandström O. Age-related changes in the neuroendocrine system of the gut: A possible role in the pathogenesis of gastrointestinal diorders in the elderly. Umeå University Medical Dissertations. Umeå: Umeå, 1999: 1-46
96. Mawe GM, Coates MD, Moses PL. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 1067-1076 [PMID: 16611266 DOI: 10.1111/j.1365-2036.2006.02858.x]
97. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996; 16: 2352-2364 [PMID: 8601815]
98. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414 [PMID: 17241888 DOI: 10.1053/j.gastro.2006.11.002]
99. Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 2013; 20: 14-21 [PMID: 23222853 DOI: 10.1097/MED.0b013e32835bc703]
100. Gershon MD. Serotonin is a sword and a shield of the bowel: serotonin plays offense and defense. Trans Am Clin Climatol Assoc 2012; 123: 268-280; discussion 280 [PMID: 23303993]
101. El-Salhy M, Mazzawi T, Gundersen D, Hatlebakk JG, Hausken T. The role of peptide YY in gastrointestinal diseases and disorders (review). Int J Mol Med 2013; 31: 275-282 [PMID: 23292145 DOI: 10.3892/ijmm.2012.1222]
102. Dubrasquet M, Bataille D, Gespach C. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep 1982; 2: 391-395 [PMID: 6125221]
103. Schjoldager BT, Baldissera FG, Mortensen PE, Holst JJ, Christiansen J. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 1988; 18: 499-503 [PMID: 3147901]
104. Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 1989; 34: 1411-1419 [PMID: 2670487]
105. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145: 2687-2695 [PMID: 15001546 DOI: 10.1210/en.2003-1338]
106. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA, Bloom SR. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54: 2390-2395 [PMID: 16046306]
107. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012; 367: 1626-1635 [PMID: 23094724 DOI: 10.1056/NEJMra1207068]
108. Jianu CS, Fossmark R, Syversen U, Hauso Ø, Waldum HL. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia. Tumour Biol 2010; 31: 373-380 [PMID: 20480408 DOI: 10.1007/s13277-010-0045-5]
109. Rindi G, Inzani F, Solcia E. Pathology of gastrointestinal disorders. Endocrinol Metab Clin North Am 2010; 39: 713-727 [PMID: 21095540 DOI: 10.1016/j.ecl.2010.08.009]
110. Seim I, El-Salhy M, Hausken T, Gundersen D, Chopin L. Ghrelin and the brain-gut axis as a pharmacological target for appetite control. Curr Pharm Des 2012; 18: 768-775 [PMID: 22236122]
111. Lee CS, Kaestner KH. Clinical endocrinology and metabolism. Development of gut endocrine cells. Best Pract Res Clin Endocrinol Metab 2004; 18: 453-462 [PMID: 15533769 DOI: 10.1016/j.beem.2004.08.008]
112. Cardoso WV, Lü J. Regulation of early lung morphogenesis: questions, facts and controversies. Development 2006; 133: 1611-1624 [PMID: 16613830 DOI: 10.1242/dev.02310]
113. Darlington GJ. Molecular mechanisms of liver development and differentiation. Curr Opin Cell Biol 1999; 11: 678-682 [PMID: 10600708]
114. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006; 43: S45-S53 [PMID: 16447274 DOI: 10.1002/ hep.20969]
115. Rawlins EL, Hogan BL. Ciliated epithelial cell lifespan in the mouse trachea and lung. Am J Physiol Lung Cell Mol Physiol 2008; 295: L231-L234 [PMID: 18487354 DOI: 10.1152/ajplung. 90209.2008]
116. Zaret KS. Regulatory phases of early liver development: paradigms of organogenesis. Nat Rev Genet 2002; 3: 499-512 [PMID: 12094228 DOI: 10.1038/nrg837]
117. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007 [PMID: 17934449 DOI: 10.1038/nature06196]
118. Barker N, van de Wetering M, Clevers H. The intestinal stem cell. Genes Dev 2008; 22: 1856-1864 [PMID: 18628392 DOI: 10.1101/gad.1674008]
119. Barker N, Clevers H. Tracking down the stem cells of the intestine: strategies to identify adult stem cells. Gastroenterology 2007; 133: 1755-1760 [PMID: 18054544 DOI: 10.1053/ j.gastro.2007.10.029]
120. Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian Theory of the origin of the four epithelial cell types. Am J Anat 1974; 141: 537-561 [PMID: 4440635 DOI: 10.1002/aja.1001410407]
121. Fontaine J, Le Lièvre C, Le Douarin NM. What is the developmental fate of the neural crest cells which migrate into the pancreas in the avian embryo? Gen Comp Endocrinol 1977; 33: 394-404 [PMID: 924129]
122. Le Douarin NM, Teillet MA. The migration of neural crest cells to the wall of the digestive tract in avian embryo. J Embryol Exp Morphol 1973; 30: 31-48 [PMID: 4729950]
123. Rawdon BB, Andrew A. Origin and differentiation of gut endocrine cells. Histol Histopathol 1993; 8: 567-580 [PMID: 8358166]
124. Hoffman J, Kuhnert F, Davis CR, Kuo CJ. Wnts as essential growth factors for the adult small intestine and colon. Cell Cycle 2004; 3: 554-557 [PMID: 15044853]
125. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ, Clevers H. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998; 19: 379-383 [PMID: 9697701 DOI: 10.1038/1270]
126. Ghia JE, Li N, Wang H, Collins M, Deng Y, El-Sharkawy RT, Côté F, Mallet J, Khan WI. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 2009; 137: 1649-1660 [PMID: 19706294 DOI: 10.1053/ j.gastro.2009.08.041]
127. Walther DJ, Peter JU, Bashammakh S, Hörtnagl H, Voits M, Fink H, Bader M. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76 [PMID: 12511643 DOI: 10.1126/science.1078197]
128. Gutknecht L, Kriegebaum C, Waider J, Schmitt A, Lesch KP. Spatio-temporal expression of tryptophan hydroxylase isoforms in murine and human brain: convergent data from Tph2 knockout mice. Eur Neuropsychopharmacol 2009; 19: 266-282 [PMID: 19181488 DOI: 10.1016/ j.euroneuro.2008.12.005]
129. Neal KB, Parry LJ, Bornstein JC. Strain-specific genetics, anatomy and function of enteric neural serotonergic pathways in inbred mice. J Physiol 2009; 587: 567-586 [PMID: 19064621 DOI: 10.1113/jphysiol.2008.160416]
130. Wendelbo I, Mazzawi T, El-Salhy M. Increased serotonin transporter immunoreactivity intensity in the ileum of patients with irritable bowel disease. Mol Med Rep 2014; 9: 180-184; Epub 2013 Nov 8 [PMID: 24213511 DOI: 10.3892/ mmr.2013.1784]
131. El-Salhy M, Wendelbo IH, Gundersen D. Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome. Mol Med Rep 2013; 7: 1241-1244 [PMID: 23426642 DOI: 10.3892/mmr.2013.1325]
132. El-Salhy M, Vaali K, Dizdar V, Hausken T. Abnormal smallintestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci 2010; 55: 3508-3513 [PMID: 20300845 DOI: 10.1007/s10620-010-1169-6]
133. El-Salhy M, Mazzawi T, Gundersen D, Hausken T. Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Mol Med Rep 2012; 6: 1223-1225 [PMID: 22992886 DOI: 10.3892/mmr.2012.1087]
134. El-Salhy M, Lomholt-Beck B, Hausken T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2010; 45: 1435-1439 [PMID: 20602602 DOI: 10.3109/00365521.2010.503965]
135. El-Salhy M, Lillebø E, Reinemo A, Salmelid L. Ghrelin in patients with irritable bowel syndrome. Int J Mol Med 2009; 23: 703-707 [PMID: 19424595]
136. El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG, Hausken T. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci 2012; 57: 873-878 [PMID: 22057239 DOI: 10.1007/s10620-011-1948-8]
137. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Chromogranin A cell density as a diagnostic marker for lymphocytic colitis. Dig Dis Sci 2012; 57: 3154-3159 [PMID: 22699394 DOI: 10.1007/s10620-012-2249-6]
138. Sjölund K, Ekman R, Wierup N. Covariation of plasma ghrelin and motilin in irritable bowel syndrome. Peptides 2010; 31: 1109-1112 [PMID: 20338210 DOI: 10.1016/ j.peptides.2010.03.021]
139. Wang SH, Dong L, Luo JY, Gong J, Li L, Lu XL, Han SP. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol 2007; 13: 6041-6047 [PMID: 18023097]
140. Park JH, Rhee PL, Kim G, Lee JH, Kim YH, Kim JJ, Rhee JC, Song SY. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoeapredominant irritable bowel syndrome. Neurogastroenterol Motil 2006; 18: 539-546 [PMID: 16771769 DOI: 10.1111/ j.1365-2982.2006.00771.x]
141. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-1664 [PMID: 15188158]
142. El-Salhy M, Wendelbo I, Gundersen D. Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. Mol Med Rep 2013; 8: 451-455 [PMID: 23778763 DOI: 10.3892/mmr.2013.1525]
143. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096-1101 [PMID: 15247174 DOI: 10.1136/ gut.2003.021154]
144. Dizdar V, Spiller R, Singh G, Hanevik K, Gilja OH, El-Salhy M, Hausken T. Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2010; 31: 883-891 [PMID: 20132151 DOI: 10.1111/j.1365-2036.2010.04251.x]
145. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-1659 [PMID: 14724817]
146. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008; 23: 1689-1694 [PMID: 19120860 DOI: 10.1111/ j.1440-1746.2008.05574.x]
147. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811 [PMID: 11076879]
148. Kim HS, Lim JH, Park H, Lee SI. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection--an observation in a small case control study. Yonsei Med J 2010; 51: 45-51 [PMID: 20046513 DOI: 10.3349/ ymj.2010.51.1.45]
149. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-357 [PMID: 15822040]
150. El-Salhy M, Danielsson A, Stenling R, Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Intern Med 1997; 242: 413-419 [PMID: 9408072]
151. Gunnarsson J, Simrén M. Peripheral factors in the pathophysiology of irritable bowel syndrome. Dig Liver Dis 2009; 41: 788-793 [PMID: 19665956 DOI: 10.1016/j.dld.2009.07.006]
152. Delgado-Aros S, Camilleri M. Visceral hypersensitivity. J Clin Gastroenterol 2005; 39: S194-203; discussion S210 [PMID: 15798485]
153. Lee OY. Asian motility studies in irritable bowel syndrome. J Neurogastroenterol Motil 2010; 16: 120-130 [PMID: 20535342 DOI: 10.5056/jnm.2010.16.2.120]
154. Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, Simrén M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007; 133: 1113-1123 [PMID: 17919487 DOI: 10.1053/ j.gastro.2007.07.024]
155. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125-132 [PMID: 4696535]
156. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52 [PMID: 7797041]
157. Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998; 115: 1263-1271 [PMID: 9797383]
158. Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, Shabsin HS, Schuster MM. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-1192 [PMID: 2323511]
159. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganière M, Verrier P, Poitras P. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-1777 [PMID: 12055583]
160. Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Evaluation of colonic sensory thresholds in IBS patients using a barostat. Definition of optimal conditions and comparison with healthy subjects. Dig Dis Sci 1994; 39: 449-457 [PMID: 8131679]
161. Camilleri M, McKinzie S, Busciglio I, Low PA, Sweetser S, Burton D, Baxter K, Ryks M, Zinsmeister AR. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772-781 [PMID: 18456567 DOI: 10.1016/j.cgh.2008.02.060]
162. Costantini M, Sturniolo GC, Zaninotto G, D'Incà R, Polo R, Naccarato R, Ancona E. Altered esophageal pain threshold in irritable bowel syndrome. Dig Dis Sci 1993; 38: 206-212 [PMID: 8093869]
163. Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995; 40: 1607-1613 [PMID: 7648957]
164. Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40: 819-827 [PMID: 7720476]
165. Accarino AM, Azpiroz F, Malagelada JR. Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology 1995; 108: 636-643 [PMID: 7875466]
166. Kanazawa M, Hongo M, Fukudo S. Visceral hypersensitivity in irritable bowel syndrome. J Gastroenterol Hepatol 2011; 26 Suppl 3: 119-121 [PMID: 21443723 DOI: 10.1111/ j.1440-1746.2011.06640.x]
167. Azpiroz F, Bouin M, Camilleri M, Mayer EA, Poitras P, Serra J, Spiller RC. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007; 19: 62-88 [PMID: 17280586 DOI: 10.1111/j.1365-2982.2006.00875.x]
168. Kanazawa M, Palsson OS, Thiwan SI, Turner MJ, van Tilburg MA, Gangarosa LM, Chitkara DK, Fukudo S, Drossman DA, Whitehead WE. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol 2008; 103: 2550-2561 [PMID: 18684175 DOI: 10.1111/j.1572-0241.2008.02066.x]
169. van der Veek PP, Van Rood YR, Masclee AA. Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 321-328 [PMID: 18258487 DOI: 10.1016/ j.cgh.2007.12.005]
170. Kuiken SD, Lindeboom R, Tytgat GN, Boeckxstaens GE. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 157-164 [PMID: 16011674 DOI: 10.1111/j.1365-2036.2005.02524.x]
171. Lee KJ, Kim JH, Cho SW. Relationship of underlying abnormalities in rectal sensitivity and compliance to distension with symptoms in irritable bowel syndrome. Digestion 2006; 73: 133-141 [PMID: 16804303 DOI: 10.1159/000094099]
172. Sabate JM, Veyrac M, Mion F, Siproudhis L, Ducrotte P, Zerbib F, Grimaud JC, Dapoigny M, Dyard F, Coffin B. Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 484-490 [PMID: 18544074 DOI: 10.1111/j.1365-2036.2008.03759.x]
173. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 Suppl 2: 15-30 [PMID: 10429737]
174. Lundgren O. Enteric nerves and diarrhoea. Pharmacol Toxicol 2002; 90: 109-120 [PMID: 12071331]
175. Gershon MD. Plasticity in serotonin control mechanisms in the gut. Curr Opin Pharmacol 2003; 3: 600-607 [PMID: 14644011]
176. Kellum JM, Albuquerque FC, Stoner MC, Harris RP. Stroking human jejunal mucosa induces 5-HT release and Clsecretion via afferent neurons and 5-HT4 receptors. Am J Physiol 1999; 277: G515-G520 [PMID: 10484375]
177. Bueno L, Fioramonti J. Visceral perception: inflammatory and non-inflammatory mediators. Gut 2002; 51 Suppl 1: i19-i23 [PMID: 12077058]
178. Cook IJ, van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987; 93: 727-733 [PMID: 3623019]
179. Bouin M, Meunier P, Riberdy-Poitras M, Poitras P. Pain hypersensitivity in patients with functional gastrointestinal disorders: a gastrointestinal-specific defect or a general systemic condition? Dig Dis Sci 2001; 46: 2542-2548 [PMID: 11713967]
180. Moriarty KJ, Dawson AM. Functional abdominal pain: further evidence that whole gut is affected. Br Med J (Clin Res Ed) 1982; 284: 1670-1672 [PMID: 6805649]
181. Chen JX, Pan H, Rothman TP, Wade PR, Gershon MD. Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am J Physiol 1998; 275: G433-G448 [PMID: 9724254]
182. Keating C, Beyak M, Foley S, Singh G, Marsden C, Spiller R, Grundy D. Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism. J Physiol 2008; 586: 4517-4530 [PMID: 18653657 DOI: 10.1113/jphysiol.2008.156984]
183. Coleman NS, Foley S, Dunlop SP, Wheatcroft J, Blackshaw E, Perkins AC, Singh G, Marsden CA, Holmes GK, Spiller RC. Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006; 4: 874-881 [PMID: 16797248 DOI: 10.1016/ j.cgh.2006.04.017]
184. Whorwell PJ, Clouter C, Smith CL. Oesophageal motility in the irritable bowel syndrome. Br Med J (Clin Res Ed) 1981; 282: 1101-1102 [PMID: 6786454]
185. Clouse RE, Eckert TC. Gastrointestinal symptoms of patients with esophageal contraction abnormalities. Dig Dis Sci 1986; 31: 236-240 [PMID: 3948627]
186. Soffer EE, Scalabrini P, Pope CE, Wingate DL. Effect of stress on oesophageal motor function in normal subjects and in patients with the irritable bowel syndrome. Gut 1988; 29: 1591-1594 [PMID: 3209118]
187. Lind CD. Motility disorders in the irritable bowel syndrome. Gastroenterol Clin North Am 1991; 20: 279-295 [PMID: 2066153]
188. van Wijk HJ, Smout AJ, Akkermans LM, Roelofs JM, ten Thije OJ. Gastric emptying and dyspeptic symptoms in the irritable bowel syndrome. Scand J Gastroenterol 1992; 27: 99-102 [PMID: 1561533]
189. Charles F, Phillips SF, Camilleri M, Thomforde GM. Rapid gastric emptying in patients with functional diarrhea. Mayo Clin Proc 1997; 72: 323-328 [PMID: 9121178 DOI: 10.1016/ s0025-6196(11)63331-4]
190. Caballero-Plasencia AM, Valenzuela-Barranco M, Herrerías-Gutiérrez JM, Esteban-Carretero JM. Altered gastric emptying in patients with irritable bowel syndrome. Eur J Nucl Med 1999; 26: 404-409 [PMID: 10199947]
191. Portincasa P, Moschetta A, Baldassarre G, Altomare DF, Palasciano G. Pan-enteric dysmotility, impaired quality of life and alexithymia in a large group of patients meeting ROME II criteria for irritable bowel syndrome. World J Gastroenterol 2003; 9: 2293-2299 [PMID: 14562396]
192. Stanghellini V, Tosetti C, Barbara G, De Giorgio R, Cogliandro L, Cogliandro R, Corinaldesi R. Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. Am J Gastroenterol 2002; 97: 2738-2743 [PMID: 12425541 DOI: 10.1111/j.1572-0241.2002.07062.x]
193. Leahy A, Besherdas K, Clayman C, Mason I, Epstein O. Abnormalities of the electrogastrogram in functional gastrointestinal disorders. Am J Gastroenterol 1999; 94: 1023-1028 [PMID: 10201477 DOI: 10.1111/j.1572-0241.1999.01007.x]
194. Evans PR, Bak YT, Shuter B, Hoschl R, Kellow JE. Gastroparesis and small bowel dysmotility in irritable bowel syndrome. Dig Dis Sci 1997; 42: 2087-2093 [PMID: 9365140]
195. Nielsen OH, Gjørup T, Christensen FN. Gastric emptying rate and small bowel transit time in patients with irritable bowel syndrome determined with 99mTc-labeled pellets and scintigraphy. Dig Dis Sci 1986; 31: 1287-1291 [PMID: 3803129]
196. Narducci F, Bassotti G, Granata MT, Pelli MA, Gaburri M, Palumbo R, Morelli A. Colonic motility and gastric emptying in patients with irritable bowel syndrome. Effect of pretreatment with octylonium bromide. Dig Dis Sci 1986; 31: 241-246 [PMID: 3948628]
197. Acharya U, Waite N, Howlett P, Tanner AR, Smith CL. Failure to demonstrate altered gastric emptying in irritable bowel syndrome. Dig Dis Sci 1983; 28: 889-892 [PMID: 6352205]
198. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660 [PMID: 10604470 DOI: 10.1038/45230]
199. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141: 4255-4261 [PMID: 11089560]
200. Hataya Y, Akamizu T, Takaya K, Kanamoto N, Ariyasu H, Saijo M, Moriyama K, Shimatsu A, Kojima M, Kangawa K, Nakao K. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab 2001; 86: 4552 [PMID: 11549707]
201. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000; 276: 905-908 [PMID: 11027567 DOI: 10.1006/ bbrc.2000.3568]
202. Fujino K, Inui A, Asakawa A, Kihara N, Fujimura M, Fujimiya M. Ghrelin induces fasted motor activity of the gastrointestinal tract in conscious fed rats. J Physiol 2003; 550: 227-240 [PMID: 12837928 DOI: 10.1113/jphysiol.2003.040600]
203. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992 [PMID: 11739476]
204. Hosoda H, Kojima M, Kangawa K. Ghrelin and the regulation of food intake and energy balance. Mol Interv 2002; 2: 494-503 [PMID: 14993401 DOI: 10.1124/mi.2.8.494]
205. Asakawa A, Ataka K, Fujino K, Chen CY, Kato I, Fujimiya M, Inui A. Ghrelin family of peptides and gut motility. J Gastroenterol Hepatol 2011; 26 Suppl 3: 73-74 [PMID: 21443714 DOI: 10.1111/j.1440-1746.2011.06638.x]
206. Dornonville de la Cour C, Lindström E, Norlén P, Håkanson R. Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. Regul Pept 2004; 120: 23-32 [PMID: 15177917 DOI: 10.1016/ j.regpep.2004.02.008]
207. Fukuda H, Mizuta Y, Isomoto H, Takeshima F, Ohnita K, Ohba K, Omagari K, Taniyama K, Kohno S. Ghrelin enhances gastric motility through direct stimulation of intrinsic neural pathways and capsaicin-sensitive afferent neurones in rats. Scand J Gastroenterol 2004; 39: 1209-1214 [PMID: 15742997]
208. Levin F, Edholm T, Schmidt PT, Grybäck P, Jacobsson H, Degerblad M, Höybye C, Holst JJ, Rehfeld JF, Hellström PM, Näslund E. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab 2006; 91: 3296-3302 [PMID: 16772353 DOI: 10.1210/jc.2005-2638]
209. Edholm T, Levin F, Hellström PM, Schmidt PT. Ghrelin stimulates motility in the small intestine of rats through intrinsic cholinergic neurons. Regul Pept 2004; 121: 25-30 [PMID: 15256270 DOI: 10.1016/j.regpep.2004.04.001]
210. Tack J, Depoortere I, Bisschops R, Delporte C, Coulie B, Meulemans A, Janssens J, Peeters T. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006; 55: 327-333 [PMID: 16216827 DOI: 10.1136/gut.2004.060426]
211. Ariga H, Tsukamoto K, Chen C, Mantyh C, Pappas TN, Takahashi T. Endogenous acyl ghrelin is involved in mediating spontaneous phase III-like contractions of the rat stomach. Neurogastroenterol Motil 2007; 19: 675-680 [PMID: 17640183 DOI: 10.1111/j.1365-2982.2007.00945.x]
212. Ariga H, Nakade Y, Tsukamoto K, Imai K, Chen C, Mantyh C, Pappas TN, Takahashi T. Ghrelin accelerates gastric emptying via early manifestation of antro-pyloric coordination in conscious rats. Regul Pept 2008; 146: 112-116 [PMID: 17913258 DOI: 10.1016/j.regpep.2007.08.022]
213. Tümer C, Oflazoǧlu HD, Obay BD, Kelle M, Taşdemir E. Effect of ghrelin on gastric myoelectric activity and gastric emptying in rats. Regul Pept 2008; 146: 26-32 [PMID: 17825442 DOI: 10.1016/j.regpep.2007.07.008]
214. Tebbe JJ, Mronga S, Tebbe CG, Ortmann E, Arnold R, Schäfer MK. Ghrelin-induced stimulation of colonic propulsion is dependent on hypothalamic neuropeptide Y1-and corticotrophin-releasing factor 1 receptor activation. J Neuroendocrinol 2005; 17: 570-576 [PMID: 16101895 DOI: 10.1111/ j.1365-2826.2005.01340.x]
215. Tack JF, Janssens J, Vantrappen G, Wood JD. Actions of 5-hydroxytryptamine on myenteric neurons in guinea pig gastric antrum. Am J Physiol 1992; 263: G838-G846 [PMID: 1476191]
216. Michel K, Sann H, Schaaf C, Schemann M. Subpopulations of gastric myenteric neurons are differentially activated via distinct serotonin receptors: projection, neurochemical coding, and functional implications. J Neurosci 1997; 17: 8009-8017 [PMID: 9315919]
217. Tack J, Coulie B, Wilmer A, Andrioli A, Janssens J. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000; 46: 468-473 [PMID: 10716674]
218. Camilleri M. Integrated upper gastrointestinal response to food intake. Gastroenterology 2006; 131: 640-658 [PMID: 16890616 DOI: 10.1053/j.gastro.2006.03.023]
219. Lal S, McLaughlin J, Barlow J, D'Amato M, Giacovelli G, Varro A, Dockray GJ, Thompson DG. Cholecystokinin pathways modulate sensations induced by gastric distension in humans. Am J Physiol Gastrointest Liver Physiol 2004; 287: G72-G79 [PMID: 14764444 DOI: 10.1152/ajpgi.00351.2003]
220. Moran TH, Ladenheim EE, Schwartz GJ. Within-meal gut feedback signaling. Int J Obes Relat Metab Disord 2001; 25 Suppl 5: S39-S41 [PMID: 11840213 DOI: 10.1038/sj.ijo.0801910]
221. Chey WY, Chang TM. Secretin, 100 years later. J Gastroenterol 2003; 38: 1025-1035 [PMID: 14673718 DOI: 10.1007/ s00535-003-1235-3]
222. Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983; 24: 405-411 [PMID: 6840614]
223. Sadik R, Stotzer PO, Simrén M, Abrahamsson H. Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. Neurogastroenterol Motil 2008; 20: 197-205 [PMID: 17999649 DOI: 10.1111/j.1365-2982.2007.01025.x]
224. Jian R, Najean Y, Bernier JJ. Measurement of intestinal progression of a meal and its residues in normal subjects and patients with functional diarrhoea by a dual isotope technique. Gut 1984; 25: 728-731 [PMID: 6735253]
225. Corbett CL, Thomas S, Read NW, Hobson N, Bergman I, Holdsworth CD. Electrochemical detector for breath hydrogen determination: measurement of small bowel transit time in normal subjects and patients with the irritable bowel syndrome. Gut 1981; 22: 836-840 [PMID: 7297914]
226. Lu CL, Chen CY, Chang FY, Lee SD. Characteristics of small bowel motility in patients with irritable bowel syndrome and normal humans: an Oriental study. Clin Sci (Lond) 1998; 95: 165-169 [PMID: 9680498]
227. Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR. Dysmotility of the small intestine in irritable bowel syndrome. Gut 1988; 29: 1236-1243 [PMID: 3197998]
228. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92: 1885-1893 [PMID: 3569764]
229. Kellow JE, Gill RC, Wingate DL. Prolonged ambulant recordings of small bowel motility demonstrate abnormalities in the irritable bowel syndrome. Gastroenterology 1990; 98: 1208-1218 [PMID: 2323514]
230. Quigley EM, Donovan JP, Lane MJ, Gallagher TF. Antroduodenal manometry. Usefulness and limitations as an outpatient study. Dig Dis Sci 1992; 37: 20-28 [PMID: 1728526]
231. Quigley EM. Intestinal manometry--technical advances, clinical limitations. Dig Dis Sci 1992; 37: 10-13 [PMID: 1728512]
232. Wang SH, Dong L, Luo JY, Li L, Zhu YL, Wang XQ, Zou BC, Gong J. [A research of migrating motor complex in patients with irritable bowel syndrome]. Zhonghua Neike Zazhi 2009; 48: 106-110 [PMID: 19549462]
233. Gorard DA, Libby GW, Farthing MJ. Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome. Gut 1994; 35: 203-210 [PMID: 8307470]
234. Zhao JH, Dong L, Hao XQ. [Small intestine motility and gastrointestinal hormone levels in irritable bowel syndrome]. Nanfang Yike Daxue Xuebao 2007; 27: 1492-1495 [PMID: 17959521]
235. Kellow JE, Eckersley CM, Jones MP. Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology 1991; 101: 1621-1627 [PMID: 1955127]
236. Thompson DG, Laidlow JM, Wingate DL. Abnormal smallbowel motility demonstrated by radiotelemetry in a patient with irritable colon. Lancet 1979; 2: 1321-1323 [PMID: 92671]
237. Kingham JG, Bown R, Colson R, Clark ML. Jejunal motility in patients with functional abdominal pain. Gut 1984; 25: 375-380 [PMID: 6706216]
238. Schmidt T, Pfeiffer A, Kaess H. Abnormal intestinal motility in irritable bowel syndrome. Gastroenterology 1996; 111: 1400-1401 [PMID: 8898662]
239. Schmidt T, Hackelsberger N, Widmer R, Meisel C, Pfeiffer A, Kaess H. Ambulatory 24-hour jejunal motility in diarrheapredominant irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 581-589 [PMID: 8789897]
240. Hellström PM, Näslund E, Edholm T, Schmidt PT, Kristensen J, Theodorsson E, Holst JJ, Efendic S. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 2008; 20: 649-659 [PMID: 18298441 DOI: 10.1111/j.1365-2982.2007.01079.x]
241. Simrén M, Castedal M, Svedlund J, Abrahamsson H, Björnsson E. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)]. Dig Dis Sci 2000; 45: 2151-2161 [PMID: 11215731]
242. Stanghellini V, Ghidini C, Maccarini MR, Paparo GF, Corinaldesi R, Barbara L. Fasting and postprandial gastrointestinal motility in ulcer and non-ulcer dyspepsia. Gut 1992; 33: 184-190 [PMID: 1541413]
243. Björnsson ES, Abrahamsson H. Interdigestive gastroduo-denal manometry in humans. Indication of duodenal phase III as a retroperistaltic pump. Acta Physiol Scand 1995; 153: 221-230 [PMID: 7625174 DOI: 10.1111/j.1748-1716.1995. tb09857.x]
244. Maljaars PW, Keszthelyi D, Masclee AA. An ileal brakethrough? Am J Clin Nutr 2010; 92: 467-468 [PMID: 20685954 DOI: 10.3945/ajcn.2010.30180]
245. Van Citters GW, Lin HC. Ileal brake: neuropeptidergic control of intestinal transit. Curr Gastroenterol Rep 2006; 8: 367-373 [PMID: 16968603]
246. Lin HC, Zhao XT, Wang L, Wong H. Fat-induced ileal brake in the dog depends on peptide YY. Gastroenterology 1996; 110: 1491-1495 [PMID: 8613054]
247. Pironi L, Stanghellini V, Miglioli M, Corinaldesi R, De Giorgio R, Ruggeri E, Tosetti C, Poggioli G, Morselli Labate AM, Monetti N. Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology 1993; 105: 733-739 [PMID: 8359644]
248. Spiller RC, Trotman IF, Adrian TE, Bloom SR, Misiewicz JJ, Silk DB. Further characterisation of the 'ileal brake' reflex in man--effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. Gut 1988; 29: 1042-1051 [PMID: 3410330]
249. Spiller RC, Trotman IF, Higgins BE, Ghatei MA, Grimble GK, Lee YC, Bloom SR, Misiewicz JJ, Silk DB. The ileal brake--inhibition of jejunal motility after ileal fat perfusion in man. Gut 1984; 25: 365-374 [PMID: 6706215]
250. Goumain M, Voisin T, Lorinet AM, Ducroc R, Tsocas A, Rozé C, Rouet-Benzineb P, Herzog H, Balasubramaniam A, Laburthe M. The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y(2) receptor: pharmacological evidence and molecular cloning. Mol Pharmacol 2001; 60: 124-134 [PMID: 11408607]
251. Souli A, Chariot J, Voisin T, Presset O, Tsocas A, Balasubramaniam A, Laburthe M, Rozé C. Several receptors mediate the antisecretory effect of peptide YY, neuropeptide Y, and pancreatic polypeptide on VIP-induced fluid secretion in the rat jejunum in vivo. Peptides 1997; 18: 551-557 [PMID: 9210175]
252. Whang EE, Hines OJ, Reeve JR, Grandt D, Moser JA, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW. Antisecretory mechanisms of peptide YY in rat distal colon. Dig Dis Sci 1997; 42: 1121-1127 [PMID: 9201071]
253. Konturek SJ, Konturek PC, Brzozowska I, Pawlik M, Sliwowski Z, Cześnikiewicz-Guzik M, Kwiecień S, Brzozowski T, Bubenik GA, Pawlik WW. Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT). J Physiol Pharmacol 2007; 58: 381-405 [PMID: 17928638]
254. Thor PJ, Krolczyk G, Gil K, Zurowski D, Nowak L. Melatonin and serotonin effects on gastrointestinal motility. J Physiol Pharmacol 2007; 58 Suppl 6: 97-103 [PMID: 18212403]
255. Lu WZ, Song GH, Gwee KA, Ho KY. The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig Dis Sci 2009; 54: 1087-1093 [PMID: 18720001 DOI: 10.1007/s10620-008-0463-z]
256. Charles F, Camilleri M, Phillips SF, Thomforde GM, Forstrom LA. Scintigraphy of the whole gut: clinical evaluation of transit disorders. Mayo Clin Proc 1995; 70: 113-118 [PMID: 7845035 DOI: 10.1016/s0025-6196(11)64277-8]
257. van der Sijp JR, Kamm MA, Nightingale JM, Britton KE, Mather SJ, Morris GP, Akkermans LM, Lennard-Jones JE. Radioisotope determination of regional colonic transit in severe constipation: comparison with radio opaque markers. Gut 1993; 34: 402-408 [PMID: 8472991]
258. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992; 102: 102-108 [PMID: 1727743]
259. Snape WJ, Carlson GM, Cohen S. Colonic myoelectric activity in the irritable bowel syndrome. Gastroenterology 1976; 70: 326-330 [PMID: 765183]
260. Snape WJ. Myoelectric and motor activity of the colon in normal and abnormal states. Scand J Gastroenterol Suppl 1984; 96: 55-60 [PMID: 6591381]
261. Sarna S, Latimer P, Campbell D, Waterfall WE. Effect of stress, meal and neostigmine on rectosigmoid electrical control activity (ECA) in normals and in irritable bowel syndrome patients. Dig Dis Sci 1982; 27: 582-591 [PMID: 7083996]
262. Latimer P, Sarna S, Campbell D, Latimer M, Waterfall W, Daniel EE. Colonic motor and myoelectrical activity: a comparative study of normal subjects, psychoneurotic patients, and patients with irritable bowel syndrome. Gastroenterology 1981; 80: 893-901 [PMID: 7202974]
263. Welgan P, Meshkinpour H, Ma L. Role of anger in antral motor activity in irritable bowel syndrome. Dig Dis Sci 2000; 45: 248-251 [PMID: 10711433]
264. Welgan P, Meshkinpour H, Hoehler F. The effect of stress on colon motor and electrical activity in irritable bowel syndrome. Psychosom Med 1985; 47: 139-149 [PMID: 4048360]
265. Katschinski M, Lederer P, Ellermann A, Ganzleben R, Lux G, Arnold R. Myoelectric and manometric patterns of human rectosigmoid colon in irritable bowel syndrome and diverticulosis. Scand J Gastroenterol 1990; 25: 761-768 [PMID: 2204105]
266. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001; 96: 1499-1506 [PMID: 11374689 DOI: 10.1111/ j.1572-0241.2001.03804.x]
267. Vassallo MJ, Camilleri M, Phillips SF, Steadman CJ, Talley NJ, Hanson RB, Haddad AC. Colonic tone and motility in patients with irritable bowel syndrome. Mayo Clin Proc 1992; 67: 725-731 [PMID: 1434910]
268. Corsetti M, Ogliari C, Marino B, Basilisco G. Perceptual sensitivity and response bias during rectal distension in patients with irritable bowel syndrome. Neurogastroenterol Motil 2005; 17: 541-547 [PMID: 16078943 DOI: 10.1111/ j.1365-2982.2005.00701.x]
269. Corsetti M, Cesana B, Bhoori S, Basilisco G. Rectal hyperreactivity to distention in patients with irritable bowel syndrome: role of distention rate. Clin Gastroenterol Hepatol 2004; 2: 49-56 [PMID: 15017632]
270. Bassotti G, de Roberto G, Chistolini F, Sietchiping-Nzepa F, Morelli O, Morelli A. Twenty-four-hour manometric study of colonic propulsive activity in patients with diarrhea due to inflammatory (ulcerative colitis) and non-inflammatory (irritable bowel syndrome) conditions. Int J Colorectal Dis 2004; 19: 493-497 [PMID: 15083326 DOI: 10.1007/ s00384-004-0604-6]
271. Bassotti G, Sietchiping-Nzepa F, De Roberto G, Chistolini F, Morelli A. Colonic regular contractile frequency patterns in irritable bowel syndrome: the 'spastic colon' revisited. Eur J Gastroenterol Hepatol 2004; 16: 613-617 [PMID: 15167165]
272. Clemens CH, Samsom M, Van Berge Henegouwen GP, Smout AJ. Abnormalities of left colonic motility in ambulant nonconstipated patients with irritable bowel syndrome. Dig Dis Sci 2003; 48: 74-82 [PMID: 12645793]
273. Clemens CH, Samsom M, Roelofs JM, van Berge Henegouwen GP, Smout AJ. Association between pain episodes and high amplitude propagated pressure waves in patients with irritable bowel syndrome. Am J Gastroenterol 2003; 98: 1838-1843 [PMID: 12907341 DOI: 10.1111/ j.1572-0241.2003.07541.x]
274. Rogers J, Henry MM, Misiewicz JJ. Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome. Gut 1989; 30: 634-641 [PMID: 2731756]
275. Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001; 48: 20-27 [PMID: 11115818]
276. Di Stefano M, Miceli E, Missanelli A, Mazzocchi S, Corazza GR. Meal induced rectosigmoid tone modification: a low caloric meal accurately separates functional and organic gastrointestinal disease patients. Gut 2006; 55: 1409-1414 [PMID: 16434428 DOI: 10.1136/gut.2005.076323]
277. Park JH, Baek YH, Park DI, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Rhee PL. Analysis of rectal dynamic and static compliances in patients with irritable bowel syndrome. Int J Colorectal Dis 2008; 23: 659-664 [PMID: 18357460 DOI: 10.1007/s00384-008-0469-1]
278. Steens J, Van Der Schaar PJ, Penning C, Brussee J, Masclee AA. Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil 2002; 14: 241-247 [PMID: 12061908]
279. Kwan CL, Davis KD, Mikula K, Diamant NE. Abnormal rectal motor physiology in patients with irritable bowel syndrome. Neurogastroenterol Motil 2004; 16: 251-263 [PMID: 15086879 DOI: 10.1111/j.1365-2982.2004.00508.x]
280. Hillsley K, Kirkup AJ, Grundy D. Direct and indirect actions of 5-hydroxytryptamine on the discharge of mesenteric afferent fibres innervating the rat jejunum. J Physiol 1998; 506 (Pt 2): 551-561 [PMID: 9490878]
281. Hillsley K, Grundy D. Sensitivity to 5-hydroxytryptamine in different afferent subpopulations within mesenteric nerves supplying the rat jejunum. J Physiol 1998; 509 (Pt 3): 717-727 [PMID: 9596794]
282. Grundy D, Hillsley K, Kirkup AJ, Richards W. Mesenteric afferent sensitivity to cholecystokinin and 5-hydroxytryptamine. Dtsch Tierarztl Wochenschr 1998; 105: 466-468 [PMID: 9932018]
283. Blackshaw LA, Grundy D. Effects of 5-hydroxytryptamine on discharge of vagal mucosal afferent fibres from the upper gastrointestinal tract of the ferret. J Auton Nerv Syst 1993; 45: 41-50 [PMID: 8227963]
284. Blackshaw LA, Grundy D. Effects of 5-hydroxytryptamine (5-HT) on the discharge of vagal mechanoreceptors and motility in the upper gastrointestinal tract of the ferret. J Auton Nerv Syst 1993; 45: 51-59 [PMID: 8227964]
285. Kirchgessner AL, Liu MT, Tamir H, Gershon MD. Identification and localization of 5-HT1P receptors in the guinea pig pancreas. Am J Physiol 1992; 262: G553-G566 [PMID: 1550243]
286. Kirchgessner AL, Liu MT, Gershon MD. In situ identification and visualization of neurons that mediate enteric and enteropancreatic reflexes. J Comp Neurol 1996; 371: 270-286 [PMID: 8835732 DOI: 10.1002/(SICI)1096-9861(19960722)371]
287. Gershon MD, Wade PR, Kirchgessner AL, Tamir H. 5-HT receptor subtypes outside the central nervous system. Roles in the physiology of the gut. Neuropsychopharmacology 1990; 3: 385-395 [PMID: 2078274]
288. Pan H, Gershon MD. Activation of intrinsic afferent pathways in submucosal ganglia of the guinea pig small intestine. J Neurosci 2000; 20: 3295-3309 [PMID: 10777793]
289. Cooke HJ, Sidhu M, Wang YZ. 5-HT activates neural reflexes regulating secretion in the guinea-pig colon. Neurogastroenterol Motil 1997; 9: 181-186 [PMID: 9347474]
290. Oddsson E, Rask-Madsen J, Krag E. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol 1978; 13: 408-416 [PMID: 675149]
291. Larsson MH, Simrén M, Thomas EA, Bornstein JC, Lindström E, Sjövall H. Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 812-820 [PMID: 17883433 DOI: 10.1111/ j.1365-2982.2007.00941.x]
292. Money ME, Camilleri M. Review: Management of postprandial diarrhea syndrome. Am J Med 2012; 125: 538-544 [PMID: 22624684 DOI: 10.1016/j.amjmed.2011.11.006]
293. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2013; 368: 578-579 [PMID: 23388017 DOI: 10.1056/NEJMc1214185]
294. Camilleri M, Coulie B, Tack JF. Visceral hypersensitivity: facts, speculations, and challenges. Gut 2001; 48: 125-131 [PMID: 11115834]
295. De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil 2004; 16: 515-531 [PMID: 15500508 DOI: 10.1111/ j.1365-2982.2004.00538.x]
296. Hotoleanu C, Popp R, Trifa AP, Nedelcu L, Dumitrascu DL. Genetic determination of irritable bowel syndrome. World J Gastroenterol 2008; 14: 6636-6640 [PMID: 19034965]
297. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Noncolonic features of irritable bowel syndrome. Gut 1986; 27: 37-40 [PMID: 3949235]
298. Locke GR, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000; 75: 907-912 [PMID: 10994826 DOI: 10.4065/75.9.907]
299. Kalantar JS, Locke GR, Zinsmeister AR, Beighley CM, Talley NJ. Familial aggregation of irritable bowel syndrome: a prospective study. Gut 2003; 52: 1703-1707 [PMID: 14633946]
300. Kanazawa M, Endo Y, Whitehead WE, Kano M, Hongo M, Fukudo S. Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. Dig Dis Sci 2004; 49: 1046-1053 [PMID: 15309899]
301. Morris-Yates A, Talley NJ, Boyce PM, Nandurkar S, Andrews G. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998; 93: 1311-1317 [PMID: 9707057 DOI: 10.1111/j.1572-0241.1998.440_j.x]
302. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001; 121: 799-804 [PMID: 11606493]
303. Lembo A, Zaman M, Jones M, Talley NJ. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther 2007; 25: 1343-1350 [PMID: 17509102 DOI: 10.1111/ j.1365-2036.2007.03326.x]
304. Wojczynski MK, North KE, Pedersen NL, Sullivan PF. Irritable bowel syndrome: a co-twin control analysis. Am J Gastroenterol 2007; 102: 2220-2229 [PMID: 17897337 DOI: 10.1111/j.1572-0241.2007.01479.x]
305. Bengtson MB, Rønning T, Vatn MH, Harris JR. Irritable bowel syndrome in twins: genes and environment. Gut 2006; 55: 1754-1759 [PMID: 17008364 DOI: 10.1136/ gut.2006.097287]
306. Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill NJ. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol 2005; 100: 1340-1344 [PMID: 15929767 DOI: 10.1111/j.1572-0241.2005.41700.x]
307. Spiller R, Garsed K. Infection, inflammation, and the irritable bowel syndrome. Dig Liver Dis 2009; 41: 844-849 [PMID: 19716778 DOI: 10.1016/j.dld.2009.07.007]
308. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988 [PMID: 19457422 DOI: 10.1053/j.gastro.2009.02.074]
309. Spiller RC. Irritable bowel syndrome: bacteria and inflammation--clinical relevance now. Curr Treat Options Gastroenterol 2007; 10: 312-321 [PMID: 17761124]
310. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007; 42 Suppl 17: 41-47 [PMID: 17238025 DOI: 10.1007/s00535-006-1925-8]
311. Sarna SK. Lessons Learnt from Post-Infectious IBS. Front Physiol 2011; 2: 49 [PMID: 21897820 DOI: 10.3389/ fphys.2011.00049]
312. Gwee KA. Post-Infectious Irritable Bowel Syndrome, an Inflammation-Immunological Model with Relevance for Other IBS and Functional Dyspepsia. J Neurogastroenterol Motil 2010; 16: 30-34 [PMID: 20535323 DOI: 10.5056/ jnm.2010.16.1.30]
313. Ghoshal UC, Park H, Gwee KA. Bugs and irritable bowel syndrome: The good, the bad and the ugly. J Gastroenterol Hepatol 2010; 25: 244-251 [PMID: 20074148 DOI: 10.1111/ j.1440-1746.2009.06133.x]
314. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome--a meta-analysis. Am J Gastroenterol 2006; 101: 1894-1899; quiz 1942 [PMID: 16928253 DOI: 10.1111/j.1572-0241.2006.00654.x]
315. Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J Pediatr Gastroenterol Nutr 2007; 45 Suppl 2: S115-S119 [PMID: 18185071 DOI: 10.1097/MPG.0b013e31812e66da]
316. Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Mawe G, Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005; 17: 863-870 [PMID: 16336502 DOI: 10.1111/j.1365-2982.2005.00719.x]
317. Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol 2010; 161: 19-27 [PMID: 20408856 DOI: 10.1111/j.1365-2249.2010.04150.x]
318. Yang GB, Lackner AA. Proximity between 5-HT secreting enteroendocrine cells and lymphocytes in the gut mucosa of rhesus macaques (Macaca mulatta) is suggestive of a role for enterochromaffin cell 5-HT in mucosal immunity. J Neuroimmunol 2004; 146: 46-49 [PMID: 14698846]
319. Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010; 1: 97-105 [PMID: 21607147 DOI: 10.4291/wjgp.v1.i3.97]
320. Wouters MM, Boeckxstaens GE. Neuroimmune mechanisms in functional bowel disorders. Neth J Med 2011; 69: 55-61 [PMID: 21411840]
321. Moran GW, Leslie FC, Levison SE, Worthington J, McLaughlin JT. Enteroendocrine cells: neglected players in gastrointestinal disorders? Therap Adv Gastroenterol 2008; 1: 51-60 [PMID: 21180514 DOI: 10.1177/1756283x08093943]